Foslevodopa, Foscarbidopa

Duodopa 240 MG/ML + 12 MG/ML Solucion Para Perfusion

240 mg/ml + 12 mg solución para perfusiónSpainMarketedAuthorised 20 Feb 2023

In other countries

The same active substances on other registers, the same brand first.

DuodopaItaly · Gel intestinale · Abbvie S.R.L.Same brand
VyalevBrazil · Abbvie Farmacêutica Ltda.Same substance
VyalevCanada · 12 MG / ML + 240 MG / ML · Solution · Abbvie CorporationSame substance
Produodopa 240 mg/ml + 12 mg/ml otopina za infuzijuCroatia · Otopina za infuziju · AbbVie d.o.o., Strojarska cesta 20, Zagreb, HrvatskaSame substance
VyalevUnited States · 120MG/10ML; 2400MG/10ML (12MG/ML · solution · AbbvieSame substance

Packs

Pack	Code	Status
DUODOPA 240 MG/ML + 12 MG/ML SOLUCION PARA PERFUSION, 7 viales de 10 ml	762282

Documents

The official texts, at the regulator.

Two medicines in one question?

Name two or more medicines and Osler runs an interaction check. A severe interaction is stated at the very top of the answer.

Discover Osler

Foslevodopa, Foscarbidopa

Duodopa 240 MG/ML + 12 MG/ML Solucion Para Perfusion

240 mg/ml + 12 mg solución para perfusiónSpainMarketedAuthorised 20 Feb 2023

Product informationAsk Osler about it

In other countries

The same active substances on other registers, the same brand first.

Packs

Pack	Code	Status
DUODOPA 240 MG/ML + 12 MG/ML SOLUCION PARA PERFUSION, 7 viales de 10 ml	762282

Documents

The official texts, at the regulator.

Two medicines in one question?

Name two or more medicines and Osler runs an interaction check. A severe interaction is stated at the very top of the answer.

Discover Osler

Summary of product characteristicsAEMPS

Package leafletAEMPS

Register entryAEMPS

Sources and licences

Compiled by Prognia from the public register below; the register’s text is the official one.

Agencia Española de Medicamentos y Productos Sanitarios

Fuente de la información: Agencia Española de Medicamentos y Productos Sanitarios www.aemps.gob.es; CIMA medicamentos, acquired 11 October 2026 UTC; each source response/update date retained.

Licence: AEMPS explicit public open-data reuse for citizens and companies; source attribution and update date required · Added 12 Oct 2026

Report an error or request removalCorrections from the holder or the register are welcome.

Prognia shows this product information for reference and learning. It is not treatment advice and can lag behind the official text. Always check the current product information and local protocols before prescribing.

At a glance

Active substances: Foslevodopa, Foscarbidopa
Strength: 240 mg/ml + 12 mg
Dosage form: solución para perfusión
Route: vía subcutánea
Register: Spain (AEMPS)
Status: Marketed
Status in the register: Autorizado, comercializado
Authorised: 20 Feb 2023
Registration: 88677
Marketing authorisation holder: Abbvie Spain, S.L.U.
Procedure: National, MRP or DCP
Supply: Uso Hospitalario